Covidien Announces First Patient Enrollment in DEFINITIVE(TM) AR Study
MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the start of patient enrollment in the ev3 DEFINITIVEā¢ AR (Anti-Restenosis) study Imelda Hospital in Belgium with Dr. Patrick Peeters.